Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.
a Department of Internal Medicine , Cleveland Clinic , Cleveland , OH , USA.
William
W
Shomali
b Department of Hematologic Oncology and Blood Disorders , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.
Cheryl
C
Redmond
b Department of Hematologic Oncology and Blood Disorders , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.
Samjhana
S
Bogati
b Department of Hematologic Oncology and Blood Disorders , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.
Cassandra
C
Zimmerman
c Department of Translational Hematology and Oncology Research , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.
Valeria
V
Visconte
c Department of Translational Hematology and Oncology Research , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.
Ali
A
Tabarroki
b Department of Hematologic Oncology and Blood Disorders , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.
Matt
M
Kalaycio
b Department of Hematologic Oncology and Blood Disorders , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.|c Department of Translational Hematology and Oncology Research , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.
Ramon V
RV
Tiu
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011724:Pyridazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*
D000925:Anticoagulants; D000970:Antineoplastic Agents; D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib